Immunostimulatory compositions and methods of manufacture
AssigneeApimed Medical Honey Limited
InventorsSwapna Gannabathula, Geoff Krissansen, Jonathan McDonald Counsell Stephens, Gregor Aaron Steinhorn
Life of this patent
Estimating the term…
Abstract
Immune-stimulatory compositions and methods of manufacture are described with an unexpectedly greater immunostimulatory effect on the immune system than the individual components alone. The compositions include a combination of arabinogalactan protein (AGP) compounds, particularly those derived from honey or with similar activity to honey derived AGP's along with apisimin proteins, peptides or functional fragments thereof, particularly those isolated from royal jelly or apisimin produced via recombinant methods.
Claims16
An immunostimulatory composition comprising a therapeutically effective amount of:
- a) honey derived AGP;
- and
- b) an isolated and/or purified apisimin protein comprising the sequence set forth in SEQ ID NO. 1 and/or one or more peptides with at least 95% homology thereto,
- wherein the concentration of honey derived AGP in the immunostimulatory composition is greater than approximately 1 μg/ml, the concentration of apisimin proteins or peptides in the immunostimulatory composition is greater than approximately 5 μg/ml, and wherein the combination of the AGP and apisimin protein and/or the one or more peptides stimulates an immune response.
A method of manufacturing an immunostimulatory composition comprising the steps of:
- a) testing the concentration of AGP in a selection of honeys, honey fractions, or honey isolates batch samples;
- b) testing the concentration of apisimin protein comprising the sequence set forth in SEQ ID NO. 1 and/or one or more peptides with at least 95% homology thereto, in the selection of honeys, honey fractions, or honey isolates batch samples;
- and
- c) selecting and blending the batch samples to prepare the immunostimulatory composition;
- wherein the concentration of AGP in the immunostimulatory composition is greater than approximately 1 μg/ml, the concentration of apisimin proteins or peptides in the immunostimulatory composition is greater than approximately 5 μg/ml, and wherein the combination of the AGP and apisimin protein and/or the one or more peptides stimulates an immune response.
Dependencies are inferred from the claim text.